Indian Active Pharmaceutical Ingredients(APIs) Industry Report, 2008-2009
  • Apr/2009
  • Hard Copy
  • USD $899
  • Pages:107
  • Single User License
    (PDF Unprintable)       
  • USD $999
  • Code: ZQ001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,499
  • Hard Copy + Single User License
  • USD $1,099

India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR as high as 18.81% during 2003-2007. And Indian ranks at the fourth in the world in terms of API output.

India currently has about 3000 API factories and 5,000 reagent factories, the key API producers including the Ranbaxy, Dr. Reddy, Cipla Ltd, Cadila Healthcare and Matrix. They are producing more than 400 sorts of API and around 10,000 kinds of reagents, satisfying over 90% of Indian domestic demand.

The pharmaceutical companies such as Dr.Reddy, Wockhardt and Sun Pharmaceuticals are also producing API. In the FY2007, 40% sales of Dr. Reddy were contributed by the API. Similarly, 19% revenues of Wockhardt and 18% revenues of Sun Pharmaceuticals were contributed by the API respectively.

Top Ten API Producers in India, 2007
Source: ResearchInChina

The API export of India will enjoy a rapid growth in the coming years, According to the Tata Strategic Management Group, Indian API export value will increase to US $12.75 billion in 2012 from US $3.75 billion in 2007.

This report gives an in-depth analysis of 28 Indian API Producers, including their profile, operating revenues, net profit, products, market distribution and future developments etc.

1. Overview of API Industry in India
1.1 Introduction to API
1.2 Status Quo and Prospects of Indian API Industry

2. Analysis on Major API producers in India
2.1 Alembic Ltd
2.2 Atul Ltd
2.3 Aurobindo Pharma Ltd
2.4 Cadila Healthcare Ltd
2.5 Cipla Ltd
2.6 Dr. Reddy’s Laboratories Limited
2.7 Dishman Pharmaceuticals &Chemicals Ltd
2.8 Divi's Laboratories Ltd
2.9 Elder Pharmaceuticals Ltd
2.10 FDC Ltd
2.11 Glenmark Pharmaceuticals Ltd
2.12 Hikal Ltd
2.13 Ind Swift Laboratories Ltd
2.14 IPCA Laboratories Ltd
2.15 JB Chemicals & Pharmaceuticals Ltd
2.16 Lupin Ltd
2.17 Matrix Laboratories Ltd
2.18 Merck Ltd
2.19 Orchid Chemicals & Pharmaceuticals Ltd
2.20 Pfizer Ltd
2.21 Piramal Healthcare Ltd
2.22 Ranbaxy Laboratories Ltd
2.23 Shasun Chemicals and Drugs Ltd
2.24 Sterling Biotech Ltd
2.25 Sun Pharmaceuticals Industries Ltd
2.26 Torrent Pharmaceuticals Ltd
2.27 Unichem Laboratories Ltd
2.28 Wockhardt Ltd
Global API Manufacturing 2007
Top 10 API producers in India, 2007
Revenue and net profit of Alembic,2003-2007
Financial highlight of Alembic, 2007-2008
Number of new products launched by Alembic, 2007-2008
Key products of animal-health of Alembic
Revenue and net profit of Atul,2003-2007
Market position of Pharmaceuticals and Intermediates Department of Atul
Revenue and net profit of Aurobindo, 2004-2008
financial Performance of Aurobindo,2006-2008
Sales of different drugs of Aurobindo
the operational statement of Aurobindo as at March 31,2008(by region)
Revenue and net profit of Cadila, 2004-2008
Strong brand of Cadila
Global operations of Zydus Cadila
Revenue break-up of Cadila
Research focus of Cadila
Strategies for growth momentum of Cadila
Scheme of Cadila for 2009
Revenue and net profit of Cipla, 2004-2008
Revenue and net profit of Dr. Reddy,2003-2007
Revenue from Key API Products of Dr. Reddy, 2006-2008
Consolidated Business-Wise Performance of Dr. Reddy
Geographic Mix of APIs of Dr. Reddy, 2007-2008
Revenue and net profit of Dishman,2003-2007
Revenue and net profit of Divis, 2004-2008
Revenue and net profit of Elder,2004 -2008
Products of Elder
Financial Performance of Elder,FY2006-08
Stocks and sales of finished goods of Elder
Revenue and assets of Elder,2007-2008
Revenue and net profit of FDC,2004-2008
Revenue and assets of FDC
Revenue and net profit of Glenmark, 2004-2008
Financial Performance of Glenmark
Production Lines & Regulatory Approvals of API of Glenmark
Four main business of Glenmark
Growth plans and targets for Glenmark
Key milestones planned for 2008-2010 of Glenmark
Revenue and net profit of Hikal, 2004-2008
Regulatory filing status of current Products of Hikal
Development of pharma pipeline of Hikal,1997-2005
Operational statement of Hikal
Revenue and net profit of Ind Swift, 2004-2008
Shareholding pattern of Ind Swift as on March 31,2008
Composition of export income of Ind Swift
Operating Expenses break-up of Ind Swift
Expenditure of R&D of Ind Swift
Revenue and net profit of IPCA, 2004-2008
Distribution of Shareholding of IPCA as on March 31,2008
Break-up of pharmaceutical sales of IPCA
Domestic branded formulations groupwise contribution for 2007-08 of IPCA
Continentwise exports of IPCA
Financial highlights of IPCA from 1998 to 2008
Revenue and net profit of JBCPL,2004 - 2008
JBCPL Composition of Sales (Formulations & APIs)
JBCPL Composition of Sales (Formulations & APIs)
Revenue and net profit of Lupin, 2004-2008
Products of Lupin,2008
Facilities of Lupin,2008
Products Coverage of Lupin,2008
Business model of Lupin,2008
Sales growth and revenue composition of Lupin,2007-2008
Lupin Consolidated Gross Sales by Market, 2004-2008
Lupin Consolidated Gross Sales by product, 2004-2008
Revenue Composition of Lupin in FY2007-08
Lupin Revenue of Exports by Product, 2004-2008
API Sales of Lupin in FY2007-08
API Key Markets
Strategy of Lupin,2008
Revenue and Net Profit of Matrix,2004-2008
Capacities and production of Matrix,2006-2007
Three principal products of Matrix,2007
Shareholding pattern of Matrix, 2008
Product group-wise performance of Matrix
Revenue and Net Profit of Merck,2004-2008
Pharmaceuticals products of Merck launched during 2008
Operational Performance of Merck, 2007-2008
Revenue and net profit of Orchid, 2004-2008
Products of Orchid ,2008
Product range of Orchid,2008
Global market reach of Orchid,2008
Orchid product development pipeline
Revenue and Net Profit of Pfizer, 2004-2008
Brands holding by Piramal,2009
Drug life-cycle of Piramal,2009
Global outsourcing partner,2009
Strategy of Piramal,2009
Revenue and net profit of Ranbaxy,2003-2007
Business model of Ranbaxy,2007
Global operation of Ranbaxy,2007
Europe-Key Markets of Ranbaxy,2007
Emerging markets of Ranbaxy,2007
Geographic sales split of Ranbaxy, 2007
Inorganic strategy of Ranbaxy,2007
Aspirations of Ranbaxy (2012)
Revenue and net profit of SCDL,2004 - 2008
Revenue and net profit of Sterling,2004 - 2008
Products structure of Sun Pharmaceuticals,2009
Revenue composition of Sun Pharmaceuticals,2009
Growing revenue of Sun Pharmaceuticals,2003-2007
Sustained profitability of Sun Pharmaceuticals,2003-2007
Successful acquisitions of Sun Pharmaceuticals,1995-2003
Peer comparison of Sun Pharmaceuticals,1992-2007
Strategy and approach of Sun Pharmaceuticals,2009
Revenue and net profit of Torrent, 2004-2008
Information in case of imported technology,2005-2007
Sales of Torrent Pharmaceuticals by regions,2006-2008
Revenue and net profit of Unichem,2004-2008
Comparison of power brands of Unichem,2006-2008
Shareholding pattern as on March 31, 2008
Financial highlights of Unichem,2005-2008
Revenue and net profit of Wockhardt,2003-2007
Biopharmaceuticals value chain of Wockhardt,2008
Sales Revenues and Profits of Wockhardt,1992-2007
Global operations of Wockhardt,2008
Operation transformation of Wockhardt in 1992, 2000 and 2007
Balanced portfolio of Wockhardt,2008
Eight acquisitions of Wockhardt,1997-2007

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号